{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-033055","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2024-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.421198+00:00","generated_at":"2026-05-31T16:06:59.013511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)","bullets":["GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.","Record adjusted EBITDA $62.3M (+5.0% YoY); cash from ops $45.0M; free cash flow $38.4M.","Human Nutrition & Health and Specialty Products segments post strong sales and earnings growth.","Launched Optifolin+ patented choline-enriched folate ingredient on May 20, 2024.","Repaid $35M revolving debt; net debt $202.8M; leverage ratio 0.9x."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-033055","json":"https://secwatch.observer/filing/0001628280-24-033055.json","markdown":"https://secwatch.observer/filing/0001628280-24-033055.md","text":"https://secwatch.observer/filing/0001628280-24-033055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000162828024033055/0001628280-24-033055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000162828024033055/bcpc-20240726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:06:59.013511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}